Ethic Inc’s Novavax NVAX Stock Holding History

Ethic Inc’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,075	Closed	-$60.5K	–	1276
2025 Q1	$60.5K	Buy	+10,075	New	+$83.3K	﹤0.01%	1132
2022 Q1	–	Sell	-2,256	Closed	-$323K	–	765
2021 Q4	$323K	Buy	+2,256	New	+$388K	0.02%	514

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ethic Inc's NVAX Position: Q2 2025 in Review

Ethic Inc sold out of Novavax (NVAX) in Q2 2025, closing a stake of 10,075 shares — an estimated $60.5K sold.

Ethic Inc first reported a position in NVAX in Q4 2021 and held it in 2 quarters. The position peaked at $323K in Q4 2021. 250 funds tracked by Wall St. Rank hold NVAX as of Q2 2025.

Ethic Inc reported no remaining Novavax position as of Q2 2025 after selling out during the quarter.
Ethic Inc sold 10,075 Novavax shares in Q2 2025, an estimated $60.5K.
Ethic Inc first reported a position in Novavax in Q4 2021 and held it in 2 quarters.
Ethic Inc's Novavax position peaked at $323K in Q4 2021.
250 funds tracked by Wall St. Rank held Novavax as of Q2 2025.

Based on Ethic Inc's 13F filing for Q2 2025, filed 30 Jul 2025.